Mirabilis raises $10.5 million, Ultreo inks deal with drugstore.com

Mirabilis Medica has raised $10.5 million to continue developing an ultrasound technology used to treat gynecological diseases. The first market for the Seattle medical device startup is uterine fibroids, benign tumors that cause cramps and bleeding for about 25 percent of women of reproductive age.

The company raised $4 million in venture funding last summer from Charter Life Sciences and vSpring Capital. Investors in the most recent round — an extension of the series A financing — include Arboretum Ventures, Split Rock Partners and Dow Venture Capital.

Founded in 2004, Mirabilis licensed the technology from the University of Washington. The company is led by Mike Connolly, a former principal at vSpring Capital who previously co-founded life science startups such as Novacept and Cohesion Technologies.

And speaking of ultrasound technologies that have been spun off from the UW, Ultreo — the Redmond ultrasound toothbrush maker backed with $11.3 million in venture funding — today said that drugstore.com will have an eight-week exclusive retail agreement to sell the $169.99 toothbrush. Until now, it was only available through dental offices and Ultreo’s Web site.